Trifluridine-Tipiracil

DRUG5 trials

Sponsors

Regeneron Pharmaceuticals, Astellas Pharma Global Development, Inc., Merck Sharp & Dohme LLC, The Methodist Hospital Research Institute, Gilead Sciences

Conditions

Advanced Microsatellite Stable Colorectal CancerAdvanced Solid TumorsGastroesophageal CancerMetastatic Colorectal Cancer (CRC)

Phase 1

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

Active, not recruitingNCT04626635

Regeneron PharmaceuticalsAdvanced Solid Tumors

Start: 2020-12-21End: 2027-03-05Updated: 2026-07-02

A Study of ASP1002 in Adults for Treatment of Solid Tumors

RecruitingNCT05719558

Astellas Pharma Global Development, Inc.Advanced Solid Tumors

Start: 2023-03-13End: 2030-05-31Target: 798Updated: 2026-07-23

Phase 2

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

RecruitingNCT06887218

The Methodist Hospital Research InstituteMetastatic Colorectal Cancer (CRC)

Start: 2025-05-08End: 2029-12-31Target: 57Updated: 2025-08-27

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

RecruitingNCT07527858

Gilead SciencesAdvanced Microsatellite Stable Colorectal Cancer

Start: 2026-05-19End: 2028-12-01Target: 170Updated: 2026-07-28

Phase 3

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Active, not recruitingNCT06356311

Merck Sharp & Dohme LLCGastroesophageal Cancer

Start: 2024-05-03End: 2027-05-06Target: 450Updated: 2026-02-27

Related Papers

A randomized study of neoadjuvant REGN7075 + cemiplimab + chemotherapy (chemo) vs cemiplimab + chemo in patients (pts) with resectable non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2025-05-28

A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results.

Journal of Clinical Oncology2024-06-017 citations

Phase 1 study of ASP1002, a bispecific antibody targeting claudin 4 (CLDN4) and CD137, in patients with locally advanced (LA) or metastatic solid tumors that express CLDN4.

Journal of Clinical Oncology2024-06-011 citations

A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors, including colorectal cancer: Trial in progress update.

Journal of Clinical Oncology2024-01-20

A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: Trial-in-progress update.

Journal of Clinical Oncology2023-01-245 citations

735 A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: initial dose-escalation results

Regular and Young Investigator Award Abstracts2022-11-013 citations

535 A phase I/II study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors

Regular and Young Investigator Award Abstracts2021-11-014 citations